News & Events
Wednesday July 10, 2019
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
- FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa - Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 26, 2020 - New Drug Application Based on Data from 38 Clinical
Monday July 08, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for Monday, July 29 SAN DIEGO , July 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, July 29, 2019 .
Tuesday June 11, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
- INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia - Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson's
Tuesday June 04, 2019
Live Audio Webcast will be on June 11, 2019 SAN DIEGO , June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, June 11, 2019 , in Rancho Palos Verdes, Calif.
Thursday May 30, 2019
Live Audio Webcast will be on June 6, 2019 SAN DIEGO , May 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019 , in New York .
Wednesday March 13, 2019
Tuesday March 12, 2019
Tuesday February 05, 2019
Tuesday January 29, 2019